on Pentixapharm Holding AG (ETR:PTP)
Pentixapharm's Financial Update and Strategic Focus for End of 2026
Pentixapharm Holding AG, a biotechnology firm, reported its Q3 and nine-month results for 2026, backed by the completion of a €20.4 million capital raise. This funding is expected to sustain operations until 2028. The company revised its full-year net loss forecast to €13 million, down from €21.6 million, due to cost deferrals and reduced amortization.
Key financial metrics show a cash reserve of €21.9 million by September 30, 2026, compared to €4.6 million in 2025. The company completed a rights offering in July 2026. Notably, Pentixapharm has confirmed the launch of its PANDA study by Q1 2027.
Recent amendments in financial statements, resulting from BaFin's concluded review, have prompted non-cash accounting adjustments impacting intangible assets and capital reserves.
The company's priorities include executing clinical programs and leveraging partnerships for future commercialization.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Pentixapharm Holding AG news